Società Coeptis Therapeutics, Inc. OTC Markets
Azioni
COEP
US19207C1045
Prodotti farmaceutici
Attività
Numero di dipendenti: 6
Dirigenti
Dirigenti | Titolo | Età | Da |
---|---|---|---|
David Mehalick
CEO | Chief Executive Officer | 56 | 28/10/22 |
Brian Cogley
DFI | Director of Finance/CFO | 38 | 17/05/23 |
Daniel Yerace
COO | Chief Operating Officer | 41 | 28/10/22 |
Colleen Delaney
CTO | Chief Tech/Sci/R&D Officer | 57 | 30/08/23 |
Christine Sheehy
CMP | Compliance Officer | 57 | 28/10/22 |
Amministratori
Amministratori | Titolo | Età | Da |
---|---|---|---|
Director/Board Member | 62 | 28/10/22 | |
Director/Board Member | 55 | 28/10/22 | |
Christine Sheehy
CMP | Compliance Officer | 57 | 28/10/22 |
Gene Salkind
BRD | Director/Board Member | 71 | 28/10/22 |
Chris Calise
BRD | Director/Board Member | 51 | 28/10/22 |
David Mehalick
CEO | Chief Executive Officer | 56 | 28/10/22 |
Daniel Yerace
COO | Chief Operating Officer | 41 | 28/10/22 |
Director/Board Member | 56 | 28/10/22 |
Classe di azioni
Voto | Quantità | Flottante | Autocontrollo | Flottante totale | |
---|---|---|---|---|---|
Azione A | 1 | 37 118 593 | 25 373 891 ( 68,36 %) | 0 | 68,36 % |
Coordinate società
Coeptis Therapeutics Holdings, Inc.
105 Bradford Road Suite 420
15090, Wexford
+
http://www.coeptistx.comSettore
Variaz. 1 gen. | Capi. | |
---|---|---|
+38,41% | 705 Mrd | |
+32,43% | 583 Mrd | |
-2,98% | 364 Mrd | |
+21,05% | 332 Mrd | |
+6,16% | 291 Mrd | |
+16,06% | 238 Mrd | |
-3,52% | 210 Mrd | |
+10,46% | 209 Mrd | |
+9,70% | 169 Mrd |